166 related articles for article (PubMed ID: 37833449)
1. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
2. Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Fasano GA; Bayard S; Chen Y; Varella L; Cigler T; Bensenhaver J; Simmons R; Swistel A; Marti J; Moore A; Andreopoulou E; Ng J; Brandmaier A; Formenti S; Ali H; Davis M; Newman L
Breast Cancer Res Treat; 2022 Feb; 192(1):163-173. PubMed ID: 35022867
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer.
Bravo-Solarte DC; Zhang F; Anampa JD
Clin Breast Cancer; 2023 Oct; 23(7):763-773.e6. PubMed ID: 37648557
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
[TBL] [Abstract][Full Text] [Related]
5. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
Zhang J; Wang W; Wang J; Luo Y; Chen S; Ma F; Xu B; Fan Y
J Oncol; 2020; 2020():8880727. PubMed ID: 33381180
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
10. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
[TBL] [Abstract][Full Text] [Related]
12. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.
Wang C; Chen Z; Zhou Y; Huang W; Zhu H; Mao F; Lin Y; Zhang Y; Guan J; Cao X; Sun Q
Gland Surg; 2021 Mar; 10(3):943-952. PubMed ID: 33842238
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer.
Guo Q; Lan T; Lu Y; Hu Z; Xu H; Wang X; Shao X; Fu X
Biomol Biomed; 2023 May; 23(3):502-509. PubMed ID: 36408954
[TBL] [Abstract][Full Text] [Related]
15. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
16. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis.
Wu C; Huang O; Wu J; Shen K; Chen X; Zhu S
Gland Surg; 2023 Oct; 12(10):1375-1386. PubMed ID: 38021197
[TBL] [Abstract][Full Text] [Related]
17. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
[TBL] [Abstract][Full Text] [Related]
19. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database.
Shum K; Hussein A; Hamm C
Med Oncol; 2022 Sep; 39(12):228. PubMed ID: 36175693
[TBL] [Abstract][Full Text] [Related]
20. Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer.
Xia LY; Xu WY; Zhao Y
PLoS One; 2022; 17(6):e0270528. PubMed ID: 35749525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
